Population pharmacokinetics of mycophenolate mofetil in autoimmune diseases

Population pharmacokinetics of mycophenolate mofetil in autoimmune diseases - PPMMAD

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53229

Enrollment

Registered

2023-07-18

Start date

2023-10-03

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune diseases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Mycophenolate mofetil use in autoimmune diseases

Exclusion criteria

Exclusion criteria: • age

Design outcomes

Primary

Measure	Time frame
MPA AUC0-12 determined on t=0, t=1 hour and t=3 hours.	—

Secondary

Measure	Time frame
Renal function, serum albumin levels, sex, ethnicity and concurrent administration of (possible) interacting drugs like proton-pump inhibitors, ciclosporin, antacids, colestyramin, sevelamer, rifampicin, telmisartan, metronidazole, ciprofloxacin, isavuconazonium and nintedanib.	—

Countries

Netherlands

Outcome results